Want to see HK:6681 full AI Analyst Report?
Top Page
BrainAurora Medical Technology Limited
(6681)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$1.00
▼(-82.46% Downside)
Action:Reiterated
Date:09/10/26
The score is held down primarily by weak financial quality: heavy losses, high leverage, and persistent cash burn outweigh strong top-line growth and healthy gross margins. Technicals add further pressure with a clear downtrend below major moving averages and bearish momentum indicators. Valuation is not supportive due to negative earnings (negative P/E) and no dividend yield.
Positive Factors
Strong Revenue Growth
Rapid revenue expansion across two consecutive years indicates growing commercial traction and market adoption. If sustained, this scale can improve operating leverage, support broader investment in the business, and provide a foundation for eventual profitability despite current losses.
Negative Factors
Deep Ongoing Losses
The company remains far from breakeven, with operating costs substantially exceeding its current revenue base. Persistent losses weaken internally generated capital, limit financial flexibility, and mean future growth may not translate into durable shareholder value without further cost improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid revenue expansion across two consecutive years indicates growing commercial traction and market adoption. If sustained, this scale can improve operating leverage, support broader investment in the business, and provide a foundation for eventual profitability despite current losses.
Read all positive factors
BrainAurora Medical Technology Limited (6681) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.71B
Dividend YieldN/A
Average Volume (3M)10.70M
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees165
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,358,278,000
10 Day Avg. Volume9,654,300
30 Day Avg. Volume10,695,500
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)69.27
Price to Sales (P/S)30.65
P/FCF Ratio-32.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)HK$471.47M
BrainAurora Medical Technology Limited Business Overview & Revenue Model
Company Description
BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the eva...
BrainAurora Medical Technology Limited Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
14
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 239.86M | 220.05M | 122.31M | 67.20M | 11.29M | 2.30M |
| Gross Profit | 103.21M | 89.45M | 54.01M | 32.06M | 3.30M | 1.30M |
| EBITDA | -274.77M | -276.68M | -167.29M | -317.63M | -470.81M | -689.82M |
| Net Income | -322.47M | -314.86M | -198.28M | -359.08M | -502.45M | -697.84M |
Balance Sheet | ||||||
| Total Assets | 1.05B | 733.20M | 599.50M | 394.85M | 418.09M | 371.30M |
| Cash, Cash Equivalents and Short-Term Investments | 658.44M | 531.78M | 343.88M | 57.58M | 287.22M | 323.74M |
| Total Debt | 556.24M | 565.76M | 388.28M | 364.07M | 328.14M | 308.76M |
| Total Liabilities | 629.79M | 637.69M | 1.06B | 727.03M | 1.51B | 1.05B |
| Stockholders Equity | 419.32M | 97.39M | -463.65M | -332.14M | -1.09B | -681.28M |
Cash Flow | ||||||
| Free Cash Flow | -74.67M | -205.75M | -167.24M | -155.00M | -119.74M | -60.31M |
| Operating Cash Flow | -67.88M | -178.03M | -149.49M | -136.87M | -100.68M | -49.21M |
| Investing Cash Flow | -105.33M | -272.88M | 125.37M | 102.55M | -334.46M | -21.48M |
| Financing Cash Flow | 116.19M | 339.27M | 315.50M | 63.53M | 139.65M | 393.61M |
BrainAurora Medical Technology Limited Technical Analysis
Negative
5.70
Price Trends
1.56
Negative
2.24
Negative
3.77
Negative
Market Momentum
-0.08
Positive
26.73
Positive
3.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6681, the sentiment is Negative. The current price of 5.7 is above the 20-day moving average (MA) of 1.46, above the 50-day MA of 1.56, and above the 200-day MA of 3.77, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 26.73 is Positive, neither overbought nor oversold. The STOCH value of 3.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6681.
BrainAurora Medical Technology Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$46.79B | 705.00 | 0.44% | 0.32% | 16.21% | -82.18% | |
58 Neutral | HK$2.45B | 26.97 | 3.02% | ― | 10.32% | 178.23% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | HK$4.35B | -30.02 | -3.40% | ― | 77.55% | 51.77% | |
51 Neutral | HK$6.74B | 25.25 | 17.36% | ― | 46.90% | ― | |
46 Neutral | HK$1.36B | -5.63 | -14.41% | ― | 2.56% | 20.20% | |
41 Neutral | HK$1.71B | -4.19 | -124.83% | ― | ― | ― |
* General Sector Average
HK:6681
BrainAurora Medical Technology Limited
1.27
-8.85
-87.45%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
44.58
-3.81
-7.88%
HK:1477
Ocumension Therapeutics
5.39
-4.12
-43.32%
HK:1521
Frontage Holdings Corp.
1.10
-0.33
-23.08%
HK:2157
Lepu Biopharma Co. Ltd. Class H
3.99
-4.29
-51.81%
HK:6622
Zhaoke Ophthalmology Ltd.
2.50
-1.52
-37.81%
BrainAurora Medical Technology Limited Corporate Events
BrainAurora defines optimal pediatric doses for cognitive digital therapeutics in major BMC Medicine study
Sep 9, 2026
BrainAurora Medical Technology has reported the publication of a major study in BMC Medicine that defines optimal digital training doses for children and adolescents with cognitive impairments using its Brain Function Information Management Platfo...
BrainAurora’s Self-Adaptive Digital Therapy Shows Strong Schizophrenia Results
Sep 2, 2026
BrainAurora Medical Technology Limited has reported new clinical research results demonstrating the efficacy of its self-adaptive computerized cognitive remediation technology for schizophrenia. The study used the company’s Brain Function In...
BrainAurora lifts revenue as it deepens push into AI cognitive digital therapeutics
Aug 28, 2026
BrainAurora Medical Technology Limited reported interim revenue of RMB119.9 million for the six months ended June 30, 2026, up 19.8% year on year, while its loss widened modestly, with total comprehensive expense at RMB134.6 million and an adjuste...
BrainAurora Schedules Board Meeting to Approve Interim 2026 Results
Aug 18, 2026
BrainAurora Medical Technology Limited, a listed medical technology company incorporated in the Cayman Islands and traded on the Hong Kong Stock Exchange, operates through a group structure focused on healthcare innovation and related services. It...
BrainAurora Wins AI Award and Publishes New Cognitive Training Trial Results
Jul 13, 2026
BrainAurora Medical Technology has achieved a runner-up award in the 3rd Xiongan Vertical Large Model Application Competition for its BrainAuGPT-based project on personalized intervention technology in the medical field. The company’s subsid...
BrainAurora Wins Xiongan AI Healthcare Competition and Unveils Key Brain Science Breakthroughs
Jun 29, 2026
BrainAurora Medical Technology has won the championship at the 2026 Xiongan International Medical and Health Technology Application Competition with its digital diagnosis and treatment platform for cognitive impairment based on large medical AI mo...
BrainAurora Shareholders Approve All Resolutions at 2026 AGM, Granting Board Wider Capital Mandates
Jun 18, 2026
BrainAurora Medical Technology Limited reported that all resolutions tabled at its June 18, 2026 annual general meeting, held online, were approved by shareholders via poll with overwhelming support. The adopted matters included the receipt of 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.